3.1 Adverse events |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Totals not selected |
3.2 Serious adverse events |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Totals not selected |
3.3 1‐Hydroxypyrene (1‐OHP) |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Totals not selected |
3.4 1‐Naphthol |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Totals not selected |
3.5 2‐Naphthol |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Totals not selected |
3.6 Carboxyhaemoglobin (COHb) |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Totals not selected |
3.7 3‐Hydroxypropylmercapturic acid (3‐HPMA) |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Totals not selected |
3.8 Monohydroxy‐3‐butenyl mercapturic acid (MHBMA) |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Totals not selected |
3.9 4‐(Methylnitrosamino)‐1‐(3‐pyridyl)‐1‐butanol (NNAL) |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Totals not selected |